Tumor Vaccines for Breast Cancer

REFERENCES

• Chaudhuri S., Cariappa A., Tang M., et al. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci USA 2000; 97: 11451–11454
   PubMed Web of Science ®Google Scholar
• Marincola F. M., Jaffee E. M., Hicklin D. J., et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181–273
   PubMedGoogle Scholar
• Campoli M., Chang CC, Oldford SA, et al. HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Dis 2004; 20: 105–125
   PubMedGoogle Scholar
• Aaltomaa S., Lipponen P., Eskelinen M., et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992; 28A: 859–864
   PubMed Web of Science ®Google Scholar
• Menard S., Tomasic G., Casalini P., et al. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 1997; 3: 817–819
   PubMed Web of Science ®Google Scholar
• Jerome K. R., Domenech N., Finn O. J. Tumor-specific cytotoxic T -cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 1993; 151: 1654–1662
   PubMed Web of Science ®Google Scholar
• Disis M. L., Calenoff E., McLaughlin G., et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994; 54: 16–20
   PubMed Web of Science ®Google Scholar
• Bishop M. R., Fowler D. H., Marchigiani D., et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886–3892
   PubMed Web of Science ®Google Scholar
• Lundqvist A., Childs R. Allogeneic hematopoietic cell transplantation as immunotherapy for solid tumors: current status and future directions. J Immunother 2005; 28: 281–288
   PubMed Web of Science ®Google Scholar
• Carella A. M., Beltrami G., Corsetti M. T., et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318–320
   PubMed Web of Science ®Google Scholar
• Janeway C.T. P., Walport M., Shlomchikm M. Immunobiology: The Immune System in Health and Disease. Garland Science Publishing, New York, NY 2005
   Google Scholar
• Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5: 987–995
   PubMed Web of Science ®Google Scholar
• Vollmer J. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9. Expert Opin Biol Ther 2005; 5: 673–682
   PubMed Web of Science ®Google Scholar
• Speiser D. E., Lienard D., Rufer N., et al. Rapid and strong human CD8+T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115: 739–746
   PubMed Web of Science ®Google Scholar
• Diefenbach A., Raulet D. H. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 2002; 188: 9–21
   PubMed Web of Science ®Google Scholar
• Smyth M. J., Swann J., Cretney E., et al. NKG2D function protects the host from tumor initiation. J Exp Med 2005; 202: 583–588
   PubMed Web of Science ®Google Scholar
• Bauer S., Groh V., Wu J., et al. Activation of NK cells and Tcells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727–729
   PubMed Web of Science ®Google Scholar
• Groh V., Rhinehart R., Secrist H., et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96: 6879–6884
   PubMed Web of Science ®Google Scholar
• Groh V., Wu J., Yee C., et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734–738
   PubMed Web of Science ®Google Scholar
• Singer G., Rebmann V., Chen Y. C., et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003; 9: 4460–4464
   PubMed Web of Science ®Google Scholar
• Zaks T. Z., Rosenberg S. A. Immunization with a peptide epitope (p369–377) from HER-2/neu leads to peptide specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+tumors. Cancer Res 1998; 58: 4902–4908
   PubMed Web of Science ®Google Scholar
• Vonderheide R. H., Hahn W. C., Schultze J. L., et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673–679
   PubMed Web of Science ®Google Scholar
• Maecker B., Sherr D. H., Vonderheide R. H., et al. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood 2003; 102: 3287–3294
   PubMed Web of Science ®Google Scholar
• Kao H., Marto J. A., Hoffmann T. K., et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001; 194: 1313–1323
   PubMed Web of Science ®Google Scholar
• Khong H. T., Yang J. C., Topalian S. L., et al. Immunization of HLA-A_0201 and/or HLADPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother 2004; 27: 472–477
   PubMed Web of Science ®Google Scholar
• Salazar L. G., Fikes J., Southwood S., et al. Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003; 9: 5559–5565
   PubMed Web of Science ®Google Scholar
• Anderson K. S., LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005; 4: 1123–1133
   PubMed Web of Science ®Google Scholar
• MacLean G. D., Miles D. W., Rubens R. D., et al. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996; 19: 309–316
   PubMed Web of Science ®Google Scholar
• Sandmaier B. M., Oparin D. V., Holmberg L. A., et al. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother 1999; 22: 54–66
   PubMed Web of Science ®Google Scholar
• Holmberg L. A., Oparin D. V., Gooley T., et al. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant 2000; 25: 1233–1241
   PubMed Web of Science ®Google Scholar
• Musselli C., Livingston P. O., Ragupathi G. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J Cancer Res Clin Oncol 127 Suppl 2001; 2: R20–R26
   Google Scholar
• Disis M. L., Pupa S. M., Gralow J. R., et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997; 15: 3363–3367
   PubMed Web of Science ®Google Scholar
• Stockert E., Jager E., Chen Y. T., et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187: 1349–1354
   PubMed Web of Science ®Google Scholar
• Sioud M., Hansen M. H. Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries. Eur J Immunol 2001; 31: 716–725
   PubMed Web of Science ®Google Scholar
• Sugita Y., Wada H., Fujita S., et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004; 64: 2199–2204
   PubMed Web of Science ®Google Scholar
• Wang X., Yu J., Sreekumar A., et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353: 1224–1235
   PubMed Web of Science ®Google Scholar
• Hodi F. S., Schmollinger J. C., Soiffer R. J., et al. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci USA 2002; 99: 6919–6924
   PubMed Web of Science ®Google Scholar
• Gnjatic S., Atanackovic D., Jager E., et al. Survey of naturally occurring CD4+T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 2003; 100: 8862–8867
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263–274
   PubMed Web of Science ®Google Scholar
• Zou W., Machelon V., Coulomb-L'Hermin A., et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7: 1339–1346
   PubMed Web of Science ®Google Scholar
• Rollins B. J. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006; 42: 760–767
   PubMed Web of Science ®Google Scholar
• Greenwald R. J., Freeman G. J., Sharpe A. H. The B7 family revisited. Annu Rev Immunol 2005; 23: 515–548
   PubMed Web of Science ®Google Scholar
• Muschen M., Moers C., Warskulat U., et al. CD95 ligand expression as a mechanism of immune escape in breast cancer. Immunology 2000; 99: 69–77
   PubMed Web of Science ®Google Scholar
• Brown J. A., Dorfman D. M., Ma F. R., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 1257–1266
   PubMed Web of Science ®Google Scholar
• Tringler B., Zhuo S., Pilkington G., et al. B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res 2005; 11: 1842–1848
   PubMed Web of Science ®Google Scholar
• Schuler G., Schuler-Thurner B., Steinman R. M. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15: 138–147
   PubMed Web of Science ®Google Scholar
• Wilcox R. A., Tamada K., Flies D. B., et al. Ligation of CD137 receptor prevents and reverses established anergy of CD8+cytolytic T lymphocytes in vivo. Blood 2004; 103: 177–184
   PubMed Web of Science ®Google Scholar
• Bansal-Pakala P., Jember A. G., Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med 2001; 7: 907–912
   PubMed Web of Science ®Google Scholar
• O'Neill D. W., Adams S., Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004; 104: 2235–2246
   PubMed Web of Science ®Google Scholar
• Gervais A., Leveque J., Bouet-Toussaint F., et al. Dendritic cells are defective in breast cancer patients: a potential role for polyamine in this immunodeficiency. Breast Cancer Res 2005; 7: R326–R335
   PubMed Web of Science ®Google Scholar
• Munn D. H., Sharma M. D., Lee J. R., et al. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297: 1867–1870
   PubMed Web of Science ®Google Scholar
• Mellor A. L., Munn D. H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762–774
   PubMed Web of Science ®Google Scholar
• Nair S. K., Morse M., Boczkowski D., et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002; 235: 540–549
   PubMed Web of Science ®Google Scholar
• Nestle F. O., Alijagic S., Gilliet M., et al. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328–332
   PubMed Web of Science ®Google Scholar
• Avigan D., Vasir B., Gong J., et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10: 4699–4708
   PubMed Web of Science ®Google Scholar
• Holtl L., Zelle-Rieser C., Gander H., et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 2002; 8: 3369–3376
   PubMed Web of Science ®Google Scholar
• O'Rourke M. G., Johnson M., Lanagan C., et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003; 52: 387–395
   PubMed Web of Science ®Google Scholar
• Small E. J. SPF., Higano C., Neumanaitis J., Valone F., Herschberg R. M. Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): Final survival data from a phase 3 randomized placebo-controlled trial. 2005 ASCO Prostate Cancer Symposium. 2005
   Google Scholar
• Morse M. A., Clay T. M., Hobeika A. C., et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005; 11: 3017–3024
   PubMed Web of Science ®Google Scholar
• Morse M. A., Nair S. K., Mosca P. J., et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003; 21: 341–349
   PubMed Web of Science ®Google Scholar
• Brossart P., Wirths S., Stuhler G., et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide pulsed dendritic cells. Blood 2000; 96: 3102–3108
   PubMed Web of Science ®Google Scholar
• Wobser M., Keikavoussi P., Kunzmann V., et al. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006; 55: 1294–1298
   PubMed Web of Science ®Google Scholar
• Otto K., Andersen M. H., Eggert A., et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 2005; 23: 884–889
   PubMed Web of Science ®Google Scholar
• Taylor-Papadimitriou J., Finn O. J. Biology, biochemistry and immunology of carcinomaassociated mucins. Immunol Today 1997; 18: 105–107
   PubMedGoogle Scholar
• Goydos J. S., Elder E., Whiteside T. L., et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996; 63: 298–304
   Google Scholar
• Reddish M., MacLean G. D., Koganty R. R., et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int J Cancer 1998; 76: 817–823
   PubMed Web of Science ®Google Scholar
• Gilewski T., Adluri S., Ragupathi G., et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 2000; 6: 1693–1701
   PubMed Web of Science ®Google Scholar
• Karanikas V., Thynne G., Mitchell P., et al. Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection. J Immunother 2001; 24: 172–183
   Web of Science ®Google Scholar
• Snijdewint F. G., von Mensdorff-Pouilly S., Karuntu-Wanamarta A. H., et al. Antibodydependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer 2001; 93: 97–106
   PubMed Web of Science ®Google Scholar
• Karanikas V., Hwang L. A., Pearson J., et al. Antibody and Tcell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997; 100: 2783–2792
   PubMed Web of Science ®Google Scholar
• Murray J. L., Gillogly M. E., Przepiorka D., et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369–377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+patients with metastatic breast and ovarian cancer. Clin Cancer Res 2002; 8: 3407–3418
   PubMed Web of Science ®Google Scholar
• Knutson K. L., Schiffman K., Cheever M. A., et al. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369–377, results in short-lived peptide specific immunity. Clin Cancer Res 2002; 8: 1014–1018
   PubMed Web of Science ®Google Scholar
• Disis M. L., Gooley T. A., Rinn K., et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide based vaccines. J. Clin. Oncol. 2002; 20: 2624–2632
   PubMed Web of Science ®Google Scholar
• Knutson K. L., Schiffman K., Disis M. L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107: 477–484
   PubMed Web of Science ®Google Scholar
• Disis M. L., Schiffman K., Guthrie K., et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 2004; 22: 1916–1925
   PubMed Web of Science ®Google Scholar
• Morse M. A., Clay T. M., Colling K., et al. HER2 dendritic cell vaccines. Clin Breast Cancer 3 Suppl 2003; 4: S164–S172
   Google Scholar
• Peoples G. E., Gurney J. M., Hueman M. T., et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005; 23: 7536–7545
   PubMed Web of Science ®Google Scholar
• Vonderheide R. H., Domchek S. M., Schultze J. L., et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+T lymphocytes. Clin Cancer Res 2004; 10: 828–839
   PubMed Web of Science ®Google Scholar
• Su Z., Dannull J., Yang B. K., et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+and CD4+T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174: 3798–3807
   PubMed Web of Science ®Google Scholar
• Parkhurst M. R., Riley J. P., Igarashi T., et al. Immunization of patients with the hTERT:540–548 peptide induces peptide reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 2004; 10: 4688–4698
   PubMed Web of Science ®Google Scholar
• Ho W. Y., Blattman J. N., Dossett M. L., et al. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 2003; 3: 431–437
   PubMed Web of Science ®Google Scholar
• Mach N., Dranoff G. Cytokine-secreting tumor cell vaccines. Curr Opin Immunol 2000; 12: 571–575
   PubMed Web of Science ®Google Scholar
• Ahlert T., Sauerbrei W., Bastert G., et al. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J Clin Oncol 1997; 15: 1354–1366
   PubMed Web of Science ®Google Scholar
• Wood G., Baynes R. Vaccination of Stage IV Breast Cancer Patients with Whole Autologous Malignant Cells and Granulocyte Mactrophage Colony Stimulating Factor. Proc Am Soc Clin Oncol 1999, abstr 168
   Google Scholar
• Dillman R. O., Beutel L. D., Barth N. M., et al. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival. Cancer Biother Radiopharm 2002; 17: 51–66
   PubMed Web of Science ®Google Scholar
• Wiseman C. L. Inflammatory breast cancer. 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy. Cancer Invest 1995; 13: 267–271
   PubMed Web of Science ®Google Scholar
• Schoof D. D., Smith J. W., II, Disis M. L., et al. Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF. Adv Exp Med Biol 1998; 451: 511–518
   PubMed Web of Science ®Google Scholar
• Jiang X. P., Yang D. C., Elliott R. L., et al. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15–3, CEA and CA125–results in immune and clinical responses in breast cancer patients. Cancer Biother Radiopharm 2000; 15: 495–505
   PubMed Web of Science ®Google Scholar
• Avigan D. Fusions of breast cancer and dendritic cells as a novel cancer vaccine. Clin Breast Cancer 3 Suppl 2003; 4: S158–S163
   Google Scholar
• Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539–3543
   PubMed Web of Science ®Google Scholar
• Wang R. F. Functional control of regulatory T cells and cancer immunotherapy. Semin Cancer Biol 2006; 16: 106–114
   PubMed Web of Science ®Google Scholar
• Khazaie K., von Boehmer H. The impact of CD4(+)CD25(+)Treg on tumor specific CD8(+) T cell cytotoxicity and cancer. Semin Cancer Biol 2006; 16: 124–136
   PubMed Web of Science ®Google Scholar
• Liyanage U. K., Moore T. T., Joo H. G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169: 2756–2761
   PubMed Web of Science ®Google Scholar
• DeLong P., Carroll R. G., Henry A. C., et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005; 4: 342–346
   PubMed Web of Science ®Google Scholar
• Curiel T. J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942–949
   PubMed Web of Science ®Google Scholar
• Dannull J., Su Z., Rizzieri D., et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115: 3623–3633
   PubMed Web of Science ®Google Scholar
• Barnett B., Kryczek I., Cheng P., et al. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005; 54: 369–377
   PubMed Web of Science ®Google Scholar
• Waterhouse P., Penninger J. M., Timms E., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla 4. Science 1995; 270: 985–988
   PubMed Web of Science ®Google Scholar
• Tivol E. A., Borriello F., Schweitzer A. N., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3: 541–547
   PubMed Web of Science ®Google Scholar
• Leach D. R., Krummel M. F., Allison J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734–1736
   PubMed Web of Science ®Google Scholar
• Hodi F. S., Mihm M. C., Soiffer R. J., et al. Biologic activity of cytotoxic T lymphocyteassociated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 2003; 100: 4712–4717
   PubMed Web of Science ®Google Scholar
• Ribas A., Camacho L. H., Lopez-Berestein G., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005; 23: 8968–8977
   PubMed Web of Science ®Google Scholar
• Phan G. Q., Yang J. C., Sherry R. M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372–8377
   PubMed Web of Science ®Google Scholar
• Sanderson K., Scotland R., Lee P., et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005; 23: 741–750
   PubMed Web of Science ®Google Scholar
• Davis T.A.T.S., Korman A., et al. MDX-010 (human anti-CTLA4): a phase 1 trial in hormone refractory prostate carcinoma (HRPC). Proc Am Soc Clin Oncol 2002; 21: 2002, abstr 74
   Google Scholar
• Attia P., Phan G. Q., Maker A. V., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23: 6043–6053
   PubMed Web of Science ®Google Scholar
• Hodi F. S., Seiden M., Butler M., et al. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). J Clin Oncol 2004. ASCO Annual Meeting Proceedings 2004; 22(145)2536
   Google Scholar
• Perou C. M., Sorlie T., Eisen M. B., et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747–752
   PubMed Web of Science ®Google Scholar
• Porter D. A., Krop I. E., Nasser S., et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res 2001; 61: 5697–5702
   PubMed Web of Science ®Google Scholar
• Altman J. D., Moss P. A., Goulder P. J., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274: 94–96
   PubMed Web of Science ®Google Scholar
• Emens L. A., Jaffee E. M. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 2005; 65: 8059–8064
   PubMed Web of Science ®Google Scholar
• Yang S., Haluska F. G. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fasmediated pathways. J Immunol 2004; 172: 4599–4608
   PubMed Web of Science ®Google Scholar
• Keane M. M., Ettenberg S. A., Nau M. M., et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 1999; 59: 734–741
   PubMed Web of Science ®Google Scholar
• Lutsiak M. E., Semnani R. T., De Pascalis R., et al. Inhibition of CD4(+)25+Tregulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862–2868
   PubMed Web of Science ®Google Scholar
• Gribben J. G., Ryan D. P., Boyajian R., et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005; 11: 4430–4436
   PubMed Web of Science ®Google Scholar